Espère Healthcare has announced changes to the range of DermaSilk men’s and children’s underwear which takes effect from December 1st 2011. DermaSilk underwear, a ‘Class 1 Medical Device’ approved for prescription use in the treatment of eczema, now has an ability to stretch to twice its size by an innovative process which overlays the DermaSilk fibroin silk completely around an elastane core. This means there is no longer any need for elasticated waist or legs, and the greater stretch and absence of side seams significantly increases patient comfort whilst retaining full clinical efficacy
Mens boxer shorts now come in three sizes instead of the previous six, and the childrens’ briefs are now available in 2 sizes for each gender instead of 6 unisex sizes. The prices of the new DermaSilk underwear remains unchanged.
All DermaSilk garments are available through chemist wholesalers, but can also be ordered directly from Espère Healthcare by calling Sales on 01234 834614
More about Espère Healthcare
Established in 2006, Espère Healthcare Ltd was set up to create and develop a totally new market in medical treatment – biofunctional textiles. A wide range of garments has been developed that are manufactured from new materials specifically designed to produce therapeutic rather than just protective effects, either on their own or in conjunction with currently used conventional medication.
DermaSilk Therapeutic Clothing is manufactured from specially knitted medical grade fibroin. This is derived from silk which has been stripped of its outer coating to make it hypoallergenic, and is used widely for medical sutures. This fabric is specially bonded with AEM 5772/5, a patented antimicrobial shield which has been used in hospitals for over 30 years and has proven ability to inhibit bacterial and fungal growth on fabrics such as operating theatre gowns. It acts by electrostatically attracting and physically puncturing bacteria and fungi. There is no chemical released from the silk to poison the cells and no chemicals or nano-particles are released onto the skin.
DermaSilk Therapeutic Clothing has been approved as a Class 1 medical device for use by the medical profession on NHS prescription since 2007. DermaSilk garments are used in the treatment and management of eczema by consultant dermatologists, GPs and nurses. Further indications have been added to the DermaSilk prescription portfolio to cover other conditions such as gravitational eczema in the elderly and epidermolysis bullosa, a severe and debilitating skin condition. Further research for the therapeutic use of DermaSilk in other conditions has shown very promising results.
The company also supply DermaTherapy Bedding, developed from a patented specially designed synthetic fabric sourced from the USA. Proven useful for treating eczema, this bedding has additional applications in pressure sore management in the elderly and infirm, acne, night sweats and night terrors in children. The fabric has an antimicrobial finish bonded to it to help counter bacteria such as MRSA and Clostridium difficile.
DermaSilkIntimo is the newest product in the range. The inclusion of 4% elastane compliments the inherent stretch properties of the silk and has led to a new range of seamless designs. The latest clinical trials have shown the efficacy of these garments in relieving symptoms in women suffering from lichen sclerosus and candida infections.
Espère are also driving the development of these fabrics into new areas, and trials are in progress for the use of DermaSilk in lymphoedema, trench foot and end of life care. Other fabric technologies are also currently being investigated.
Espère Healthcare Ltd is the Distributor of DermaTherapy Bedding in the UK and Ireland.
DermaTherapy® is a registered trademark of Precision Fabrics Group Inc.
Contact details
For media information contact Colin Caldicott, Ultimedia PR
Tel: 01767 601470 e-mail: colin@ultimediapr.co.uk
For technical information contact Chris Steeples, joint managing director Espère Healthcare
Tel 01234 834614 email: chris@esperehealth.co.uk


















I suppose it would be useful for the Head of Communications and Engagement to be an expert in communications and engagement, otherwise what would be the point of appointing them to a role paying between £60,671-£73,351 a year?




